BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of “Moderate Buy” by Brokerages

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given an average recommendation of “Moderate Buy” by the fifteen research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $378.4286.

A number of research firms recently commented on ONC. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Morgan Stanley reissued an “overweight” rating and set a $405.00 price objective on shares of BeOne Medicines in a report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Finally, Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target for the company in a research report on Monday, January 12th.

Insider Transactions at BeOne Medicines

In other news, CEO John Oyler sold 24,369 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total value of $7,380,639.03. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Xiaobin Wu sold 3,991 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $380.43, for a total transaction of $1,518,296.13. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 128,610 shares of company stock worth $41,114,068. 6.62% of the stock is owned by company insiders.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Anchor Investment Management LLC acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd purchased a new position in BeOne Medicines during the second quarter valued at approximately $28,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines during the second quarter valued at approximately $35,000. Farther Finance Advisors LLC acquired a new position in BeOne Medicines in the second quarter valued at approximately $39,000. Finally, CWM LLC boosted its position in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $350.00 on Friday. BeOne Medicines has a fifty-two week low of $196.45 and a fifty-two week high of $385.22. The company has a market cap of $38.38 billion, a PE ratio of 686.27 and a beta of 0.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The business has a 50-day simple moving average of $326.98 and a two-hundred day simple moving average of $321.91.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.